Ipamorelin

Ipamorelin was developed in the late 1990s during efforts to refine growth hormone secretagogues—compounds designed to stimulate endogenous growth hormone release. Earlier secretagogues could also affect ACTH, cortisol or prolactin, making it difficult to isolate growth hormone signaling in experimental models. In 1998, researchers described ipamorelin as a selective pentapeptide secretagogue that produced growth hormone release with comparatively little ACTH or cortisol response.¹ A human pharmacokinetic–pharmacodynamic study followed in 1999, characterizing its short exposure profile and dose-related growth hormone response.² Subsequent animal studies examined bone growth, bone formation and metabolic effects, while a later Phase 2 trial evaluated ipamorelin in postoperative ileus.³ ⁴ ⁵ The clinical endpoint in that trial was not significantly improved, illustrating the difference between measurable hormone release and proven therapeutic benefit. This development history established ipamorelin as a useful research tool for separating ghrelin-receptor-mediated growth hormone release from broader pituitary hormone activity. It remains investigational, and long-term controlled human evidence is limited.

Ipamorelin activates growth hormone secretagogue receptor 1a (GHSR-1a), the receptor normally stimulated by ghrelin. Receptor activation on pituitary somatotroph cells produces a rapid, short-lived increase in growth hormone release.⁶ ² ⁷ A defining feature is relative endocrine selectivity. In early animal and human studies, ipamorelin stimulated growth hormone at exposures that produced comparatively little ACTH, cortisol or prolactin response.⁶ ² This makes it useful for examining GHSR-mediated growth hormone signaling with less interference from other pituitary pathways. GHSR-1a and the GHRH receptor use distinct upstream signals. Experimental research on growth hormone secretagogues indicates that simultaneous GHSR and GHRH stimulation can produce a larger growth hormone response than either pathway alone.⁸ ⁹ ¹⁰ Growth hormone can then promote downstream IGF-1 production, although evidence cited for sustained IGF-1 elevation often comes from GHRH-analog studies rather than ipamorelin alone.¹¹ The receptor-level mechanism is supported by preclinical and acute human research, but long-term functional outcomes and chronic safety remain less well characterized.